Diabetes Screening and Management in PCOS

Initial Metabolic Screening

All women with PCOS require screening for type 2 diabetes at diagnosis using a 2-hour 75-gram oral glucose tolerance test (OGTT) plus fasting lipid profile, regardless of body weight, as insulin resistance occurs independent of BMI 1, 2, 3
Perform a 2-hour OGTT with 75-gram glucose load to detect both diabetes and impaired glucose tolerance, as this is the preferred test over fasting glucose alone or HbA1c 1, 2, 3
Obtain a complete fasting lipid profile including total cholesterol, LDL, HDL, and triglycerides at diagnosis 1, 3
Insulin resistance in PCOS creates an atherogenic lipid profile with elevated triglycerides, increased small dense LDL, and decreased HDL 1
Calculate BMI and waist-hip ratio to assess central obesity 1
Examine for acanthosis nigricans on neck, axillae, and skin folds, which indicates underlying insulin resistance 1, 2, 3
Measure blood pressure, as cardiovascular disease risk is increased 2, 3

Using OGTT results, diagnose diabetes if fasting plasma glucose ≥126 mg/dL or 2-hour post-glucose load ≥200 mg/dL 4, 1
Diagnose prediabetes if fasting glucose 100-125 mg/dL or 2-hour glucose 140-199 mg/dL 4

Screen more frequently (annually) if prediabetes is detected or if additional risk factors develop 4

Initiate lifestyle intervention immediately targeting 5% weight loss through diet, exercise, and behavioral strategies if normal glucose tolerance 1, 2
Implement intensive lifestyle modification as first-line therapy if prediabetes (IGT/IFG) is detected 1
Add metformin if lifestyle intervention fails to improve glucose tolerance after 3-6 months if prediabetes (IGT/IFG) is detected 1
Metformin improves insulin sensitivity, maintains or improves glucose tolerance over time, and tends to decrease weight 1
Refer for comprehensive diabetes management per standard diabetes care guidelines if diabetes is diagnosed 4

Do not rely on fasting glucose or HbA1c alone for screening—these tests miss a substantial proportion of glucose abnormalities in PCOS patients 1
Do not skip screening in lean women—insulin resistance and dysglycemia occur independent of BMI in PCOS 1
Do not overlook acanthosis nigricans, as it may rarely indicate associated insulinoma or gastric adenocarcinoma 1
Do not forget lipid screening—the insulin-resistant state creates particularly atherogenic lipid profiles requiring monitoring 1
Do not delay screening—your patient at age 26 meets criteria for immediate testing due to PCOS diagnosis 4

Measure thyroid-stimulating hormone (TSH) and prolactin to exclude other causes of hyperandrogenism 2, 3
Measure total testosterone or free/bioavailable testosterone to assess androgen excess severity 2, 3